What is the recommended acute management and treatment protocol for an acute intracranial hemorrhage?

Treatment of Acute Intracranial Hemorrhage

Admit all patients with acute ICH to a stroke unit or neuro-intensive care unit immediately, as this reduces both death and dependency compared to general ward care 1, 2.

Initial Assessment and Stabilization

Immediate Actions

• Discontinue all antithrombotic agents immediately upon ICH diagnosis or suspicion 3
• Obtain non-contrast head CT to confirm diagnosis and assess hematoma volume, location, and presence of hydrocephalus
• Check coagulation parameters (INR, aPTT, platelet count) and renal function urgently
• Establish goals of care with patient/family, but defer DNR decisions for 24-48 hours to allow response to therapy 1

Blood Pressure Management

Target systolic BP <140 mmHg within 1 hour for patients presenting within 6 hours of symptom onset 2. This approach is safe and may improve outcomes compared to targeting <180 mmHg. Avoid precipitous drops ≥60 mmHg within 1 hour, as this may worsen outcomes. No specific antihypertensive agent is superior—use what achieves rapid, sustained control with minimal variability.

Anticoagulation Reversal

Warfarin/Vitamin K Antagonists (INR ≥1.4)

Administer prothrombin complex concentrate (PCC) plus vitamin K 10 mg IV immediately 1, 3:

• Preferred: 4-factor or 3-factor PCC (dose based on weight, INR, and PCC type)
• Alternative if PCC unavailable: Fresh frozen plasma 10-15 mL/kg IV (but requires longer infusion time and larger volumes)
• Recheck INR 15-60 minutes post-PCC, then every 6-8 hours for 24-48 hours
• If INR remains ≥1.4 after 24-48 hours, redose vitamin K 10 mg IV
• Do NOT use recombinant Factor VIIa—it increases thromboembolic risk without clinical benefit 1, 3

Direct Oral Anticoagulants (DOACs)

For dabigatran:

• Administer idarucizumab 5 g IV in two divided doses if drug taken within 3-5 half-lives or if renal insufficiency present 3
• If idarucizumab unavailable and renal insufficiency present: consider hemodialysis
• Activated charcoal 50 g (if within 2 hours of ingestion and patient intubated or low aspiration risk)

For factor Xa inhibitors (rivaroxaban, apixaban, edoxaban):

• Administer 4-factor PCC 50 U/kg IV OR activated PCC (FEIBA) 50 U/kg IV if taken within 3-5 half-lives 3
• Alternative: Andexanet alfa (where available)
• Activated charcoal 50 g (if within 2 hours of ingestion)
• Do NOT use rFVIIa or FFP for DOAC reversal

Heparin

For full-dose unfractionated heparin:

• Protamine sulfate 1 mg per 100 units of heparin given in previous 2-3 hours (maximum 50 mg single dose) 4, 5, 3
• Recheck aPTT; if still elevated, redose protamine 0.5 mg per 100 units heparin

For therapeutic LMWH (enoxaparin):

• If given within 8 hours: protamine 1 mg per 1 mg enoxaparin (max 50 mg)
• If given 8-12 hours prior: protamine 0.5 mg per 1 mg enoxaparin
• Do NOT routinely reverse prophylactic subcutaneous heparin unless aPTT significantly prolonged

Thrombolytic-Associated ICH

Administer cryoprecipitate 10 units initial dose plus platelets 6-8 units to rapidly correct fibrinolytic state 4, 5. This carries 60% 30-day mortality—aggressive reversal is critical.

Antiplatelet Agents

Stop aspirin, clopidogrel, and other antiplatelet agents immediately 1. No RCT evidence exists for platelet transfusion, but consider in patients requiring urgent surgery or with ongoing expansion.

Neurosurgical Consultation

Mandatory Urgent Consultation

• Cerebellar hemorrhage with altered consciousness or brainstem symptoms 1
• Acute hydrocephalus requiring external ventricular drain (EVD) 1
• Supratentorial ICH >20-30 mL with GCS 5-12 (for consideration of minimally invasive surgery)

Surgical Considerations

Routine craniotomy does NOT improve outcomes for most supratentorial ICH 1, 2. However:

• Minimally invasive hematoma evacuation (endoscopic or stereotactic aspiration ± thrombolysis) reduces mortality in patients with supratentorial ICH >20-30 mL and GCS 5-12 6
• Early surgery may benefit select patients with GCS 9-12
• Cerebellar hemorrhage with mass effect requires urgent surgical evaluation

Additional Management

Seizure Management

• No role for prophylactic anticonvulsants 1
• Treat only if seizures occur

Intracranial Pressure

• Consider ICP monitoring in patients with GCS ≤8, significant mass effect, or hydrocephalus
• Target ICP <22 mmHg and CPP 50-70 mmHg (extrapolated from TBI literature)

Venous Thromboembolism Prophylaxis

• Use intermittent pneumatic compression immediately 2
• Do NOT use graduated compression stockings (ineffective and may worsen outcomes)
• Pharmacologic prophylaxis timing remains uncertain—balance thrombotic vs. hemorrhagic risk individually

Temperature and Glucose Control

• Treat fever aggressively (though optimal strategy unclear from RCTs)
• Maintain normoglycemia

Avoid Harmful Interventions

• Do NOT use dexamethasone 2
• Do NOT use recombinant Factor VIIa in non-anticoagulated patients 2

Restarting Anticoagulation

For patients with strong indications (mechanical valve, high-risk atrial fibrillation):

• Consider restarting warfarin at 7-10 days in very high thrombotic risk patients with deep ICH 4, 5
• Avoid restarting in elderly patients with lobar ICH (likely amyloid angiopathy—use antiplatelet instead)
• Consult stroke specialist, cardiologist, and hematologist for individualized decision

Key Pitfalls to Avoid

1. Early prognostication: Avoid withdrawal of care decisions in first 24-48 hours—outcomes are difficult to predict acutely
2. Delayed reversal: Coagulopathy reversal must occur within minutes to hours, not hours to days
3. Excessive BP lowering: Drops >60 mmHg in 1 hour may worsen outcomes
4. Using FFP instead of PCC: PCC acts faster with lower fluid volumes and better INR correction
5. Routine craniotomy: Does not improve outcomes in most supratentorial ICH